167 related articles for article (PubMed ID: 14968328)
1. [Complete remission of cutaneous satellite and in-transit metastases. After intralesional therapy with interleukin-2 in 2 patients with malignant melanoma].
Pföhler C; Steinhäuser S; Wagner A; Ugurel S; Tilgen W
Hautarzt; 2004 Feb; 55(2):171-5. PubMed ID: 14968328
[TBL] [Abstract][Full Text] [Related]
2. [Experience in the treatment of cutaneous in-transit melanoma metastases and satellitosis with intralesional interleukin-2].
Dehesa LA; Vilar-Alejo J; Valerón-Almazán P; Carretero G
Actas Dermosifiliogr; 2009 Sep; 100(7):571-85. PubMed ID: 19715642
[TBL] [Abstract][Full Text] [Related]
3. 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series.
Shi VY; Tran K; Patel F; Leventhal J; Konia T; Fung MA; Wilken R; Garcia MS; Fitzmaurice SD; Joo J; Monjazeb AM; Burrall BA; King B; Martinez S; Christensen SD; Maverakis E
J Am Acad Dermatol; 2015 Oct; 73(4):645-54. PubMed ID: 26259990
[TBL] [Abstract][Full Text] [Related]
4. [Imiquimod, pegylated interferon-alpha-2b and interleukin-2 in the treatment of cutaneous melanoma metastases].
Loquai C; Nashan D; Metze D; Beiteke U; Rüping KW; Luger TA; Grabbe S
Hautarzt; 2004 Feb; 55(2):176-81. PubMed ID: 14968329
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases.
Radny P; Caroli UM; Bauer J; Paul T; Schlegel C; Eigentler TK; Weide B; Schwarz M; Garbe C
Br J Cancer; 2003 Nov; 89(9):1620-6. PubMed ID: 14583759
[TBL] [Abstract][Full Text] [Related]
6. Durability of Complete Response to Intralesional Interleukin-2 for In-Transit Melanoma.
Khoury S; Knapp GC; Fyfe A; Monzon J; Temple-Oberle C; McKinnon GJ
J Cutan Med Surg; 2021; 25(4):364-370. PubMed ID: 33529083
[TBL] [Abstract][Full Text] [Related]
7. Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream.
Garcia MS; Ono Y; Martinez SR; Chen SL; Goodarzi H; Phan T; Wehrli LN; Miyamura Y; Fung MA; Maverakis E
Melanoma Res; 2011 Jun; 21(3):235-43. PubMed ID: 21464773
[TBL] [Abstract][Full Text] [Related]
8. Intra-lesional interleukin-2 for the treatment of in-transit melanoma.
Boyd KU; Wehrli BM; Temple CL
J Surg Oncol; 2011 Dec; 104(7):711-7. PubMed ID: 21744347
[TBL] [Abstract][Full Text] [Related]
9. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma.
Bong AB; Bonnekoh B; Franke I; Schön M; Ulrich J; Gollnick H
Dermatology; 2002; 205(2):135-8. PubMed ID: 12218228
[TBL] [Abstract][Full Text] [Related]
10. Intralesional therapy for in-transit and satellite metastases in melanoma.
Feeney KJ; Mastrangelo MJ
Surg Oncol Clin N Am; 2015 Apr; 24(2):299-308. PubMed ID: 25769713
[TBL] [Abstract][Full Text] [Related]
11. Intralesional granulocyte-monocyte colony-stimulating factor followed by subcutaneous interleukin-2 in metastatic melanoma: a pilot study in elderly patients.
Ridolfi L; Ridolfi R; Ascari-Raccagni A; Fabbri M; Casadei S; Gatti A; Trevisan G; Righini MG
J Eur Acad Dermatol Venereol; 2001 May; 15(3):218-23. PubMed ID: 11683284
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma.
Green DS; Bodman-Smith MD; Dalgleish AG; Fischer MD
Br J Dermatol; 2007 Feb; 156(2):337-45. PubMed ID: 17223875
[TBL] [Abstract][Full Text] [Related]
13. Intralesional immunotherapy as a strategy to treat melanoma.
Nouri N; Garbe C
Expert Opin Biol Ther; 2016; 16(5):619-26. PubMed ID: 26898656
[TBL] [Abstract][Full Text] [Related]
14. The intralesional interleukin-2 is an adequate palliative treatment in cutaneous metastases of melanoma.
Menis D; Monsalvez-Honrubia V; Maroñas-Jiménez L; Morales-Raya C; Ortiz-Romero PL
G Ital Dermatol Venereol; 2017 Aug; 152(4):400-401. PubMed ID: 28621122
[No Abstract] [Full Text] [Related]
15. Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up.
Weide B; Eigentler TK; Pflugfelder A; Leiter U; Meier F; Bauer J; Schmidt D; Radny P; Pföhler C; Garbe C
Cancer Immunol Immunother; 2011 Apr; 60(4):487-93. PubMed ID: 21174093
[TBL] [Abstract][Full Text] [Related]
16. Detailed protocol for administration of intralesional IL-2 for the treatment of Stage IIIc and IV M1a metastatic melanoma based on current NCCN guidelines.
Patel F; Wilken R; Burrall B; Martinez S; Wells V; King B; Maverakis E
Dermatol Online J; 2014 Nov; 20(11):. PubMed ID: 25419744
[TBL] [Abstract][Full Text] [Related]
17. Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanoma.
Ridolfi L; Ridolfi R
Hepatogastroenterology; 2002; 49(44):335-9. PubMed ID: 11995445
[TBL] [Abstract][Full Text] [Related]
18. Intra-lesional interleukin-2 therapy for in transit melanoma.
Temple-Oberle CF; Byers BA; Hurdle V; Fyfe A; McKinnon JG
J Surg Oncol; 2014 Mar; 109(4):327-31. PubMed ID: 24453036
[TBL] [Abstract][Full Text] [Related]
19. Intralesional agents in the management of cutaneous malignancy: a review.
Good LM; Miller MD; High WA
J Am Acad Dermatol; 2011 Feb; 64(2):413-22. PubMed ID: 20334952
[TBL] [Abstract][Full Text] [Related]
20. T Cells Dominate the Local Immune Response Induced by Intralesional IL-2 in Combination with Imiquimod and Retinoid for In-Transit Metastatic Melanoma.
Ogawa H; Luxardi G; Kirane A; Kulkarni R; Monjazeb AM; Cheng MY; Ma C; Maverakis E
J Invest Dermatol; 2018 Jun; 138(6):1442-1445. PubMed ID: 29291382
[No Abstract] [Full Text] [Related]
[Next] [New Search]